support@mellalta.com   +1 (304) 470-2225

Anti-Neutralizing Antibodies (NAbs) Gene Therapies-Pipeline Analytics 2021

$2,500.00$7,500.00

Anti-Neutralizing Antibodies (NAbs) Gene Therapies report covers the Anti-Neutralizing Antibodies (NAbs) Gene Therapies market opportunity providing Key Competitive Analysis, 20+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports covers pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. NAbs inhibitor’s reports add a value in terms of providing the description of clinical stage product with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.

Clear
SKU: MM202042 Category:

Description

Development of Anti Neutralizing Antibodies (NAbs) is currently the most serious complication during the Gene Therapy treatment, as it makes replacement therapy ineffective and occurs in approximately 30% and 5% of patients. Tremendous progress has been achieved in the last several years in overcoming this formidable barrier and extending therapy to patients who have pre-existing neutralizing antibodies, either because of infection with wild-type AAV or prior treatment with an AAV vector.

In this report, Mellalta Meets provides an in-depth analyzes anti-Nabs gene therapies covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy area, investments, and acquisition trends. Currently, there are more than 20 candidate anti-Nabs gene therapies products currently under evaluation in clinical and preclinical studies. The major key players operating in the market are Sarepta Therapeutics, UniQure, Spark Therapeutics and many more which have robust clinical pipeline of anti-Nabs gene therapies candidates.

As per analysis, the development pipeline is full of different technological aspect which can help in redosing, suppressing the neutralizing antibodies as well as ability to give gene therapies even in presence of Nabs.

Key Highlights of Anti Neutralizing Antibodies (NAbs) Gene Therapies Report

  • There are ~11 products in the Preclinical stage of development, representing 48% of the total share of the developing neutralizing antibodies (NAbs) landscape. Remaining 52% has been contributed by Phase I/II (35%); Phase II (9%); Phase III & Phase I (4%).

Anti Neutralizing Antibodies (NAbs) Gene Therapies Pipeline Landscape

  • The pipeline of Neutralizing Antibodies is dominated by biotech companies headquartered in the United States with the American companies holding the top ten positions. They represent ~95% of all the pipeline Neutralizing Antibodies in clinical stages.
  • Metabolic Disorders represents ~ 35% of the total NAbs therapies while the therapy areas namely Ophthalmology (22%); Mental, Behavioural and Neurodevelopmental disorders (13%); Musculoskeletal Diseases (13%); Hematology (9%); CNS Disorder (4%) and Respiratory Diseases (4%) occupy the remaining therapy area of Neutralizing antibodies (NAbs).
  • The pipeline of Neutralizing Antibodies (NAbs) therapies is dominated by the Preclinical (11); Phase I/II (8); Phase II (2) assets and Phase I & Phase III (1) assets.
  • To be continued…

Report Coverage:

  • Indication Prioritisation: Anti Neutralizing Antibodies (NAbs) Gene Therapies market potential based on Indications
  • Business Transactions & Strategies: Key collaborations and deal values
  • Anti Neutralizing Antibodies (NAbs) Gene Therapies Pipeline Development: Product Profiles, Clinical Trials & Results
  • Anti Neutralizing Antibodies (NAbs) Gene Therapies Acquisition Targets
  • Anti Neutralizing Antibodies (NAbs) Gene Therapies Competitive Intelligence
  • Recent & Upcoming events

Additional information

Price

2-3 User License, Enterprise License, Single User License, Site User License

Table of Contents

  • REPORT OVERVIEW
  • OVERVIEW
    • Neutralizing Antibodies (NAbs) Against AAV- Overview
    • Diagnostic tools for Nabs detection
    • Diagnostic tools for NAbs detection: Limitations
    • Current Challenges with NAbs in Gene Therapy
    • Methods of circumventing NAbs in Gene therapy
  • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES PIPELINE ANALYSIS BY PHASES
    • Overview
    • Assets by Indication/Phase
    • Pipeline Products by Stage of Development
    • Neutralizing Antibodies Competitive Landscape
    • Pipeline Products by Company and Phases
    • Pipeline Products by Therapy Area
    • Pipeline Products by Indication and Phases
    • Neutralizing Antibodies (NAbs) Clinical & Regulatory Timelines
  • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES ACQUISITIONS,LICENSING AND COLLABORATION DEALS
    • Neutralizing Antibodies (NAbs) Acquisitions, Licensing and Deal values
    • Neutralizing Antibodies (NAbs) Acquisitions, Licensing by Transaction type and total amount size by Phases
    • Promising Technology Under development
  • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES PIPELINE LANDSCAPE
    • Profile at Glance
    • Late-Stage Assets Comparisons At–a–glance
    • Neutralizing Antibodies (NAbs) Pipeline Drug Profiles
      • Phase III
        • uniQure: AMT-061
          • Product Profile & Description
          • Collaborations
          • Other Developments 
          • Clinical Trials
        • Phase II
          • Sarepta Therapeutics/Roche:SRP-9001
            • Product Profile & Description
            • Collaborations
            • Other Developments 
            • Clinical Trials 
          • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES PIPELINE LANDSCAPE
            • Sarepta Therapeutics: SRP-5051
              • Product Profile & Description
              • Collaborations
              • Other Developments 
              • Clinical Trials
            • Phase I/II
              • Spark Therapeutics/Roche: SPK-8016
                • Product Profile & Description
                • Collaborations
                • Other Developments 
                • Clinical Trials
              • Taysha Gene Therapies: TSHA -101
                • Product Profile & Description
                • Collaborations
                • Other Developments 
                • Clinical Trials 
              • 4D Molecular Therapeutics: 4D-125
                • Product Profile & Description
                • Collaborations
                • Other Developments 
                • Clinical Trials 
              • Editas Medicine: EDIT-101
                • Product Profile & Description
                • Collaborations
                • Other Developments 
                • Clinical Trials
              • 4D Molecular Therapeutics:4D-310
                • Product Profile & Description
                • Collaborations
                • Other Developments 
                • Clinical Trials
              • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES PIPELINE LANDSCAPE
                • Asklepios BioPharmaceutical: ACT-101
                  • Product Profile & Description
                  • Collaborations
                  • Other Developments 
                  • Clinical Trials
                • Passage Bio: PBGM-01
                  • Product Profile & Description
                  • Collaborations
                  • Other Developments 
                  • Clinical Trials
                • Astellas Gene Therapies: AT-845
                  • Product Profile & Description
                  • Collaborations
                  • Other Developments 
                  • Clinical Trials
                • Phase I 
                  • 4D Molecular Therapeutics: 4D-110
                    • Product Profile & Description
                    • Collaborations
                    • Other Developments 
                    • Clinical Trials 
                  • Preclinical
                    • Abeona Therapeutics: ABO-401
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • Abeona Therapeutics: ABO-50X
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • Selecta Biosciences: MMA-101
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • Taysha Gene Therapies: TSHA-102
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • Taysha Gene Therapies: TSHA-103
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • Taysha Gene Therapies: TSHA-104
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • 4D Molecular Therapeutics:4D-150
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • Hansa Biopharma AB/Sarepta Therapeutics:Imlifidase
                      • Product Profile & Description
                      • Collaborations
                      • Other Developments 
                    • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES PIPELINE LANDSCAPE
                      • 4D Molecular Therapeutics:4D-710
                        • Product Profile & Description
                        • Collaborations
                        • Other Developments 
                      • LogicBio Therapeutics:AAV sL65 Capsid
                        • Product Profile & Description
                        • Collaborations
                        • Other Developments 
                      • StrideBio: STRX-110
                        • Product Profile & Description
                        • Collaborations
                        • Other Developments 
                      • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES MARKET OVERVIEW
                        • Current Market Scenario
                        • Market Potential of Neutralizing Antibodies Market
                        • Market Potential of Neutralizing Antibodies Market Barriers & Challenges
                      • ANTI-NEUTRALIZING ANTIBODIES (NABS) GENE THERAPIES FUTURE PROSPECTS
                      • SWOT ANALYSIS
                      • APPENDIX

Companies Coverage

  • Abeona Therapeutics
  • Asklepios BioPharmaceutical
  • Astellas Gene Therapies
  • Editas Medicine
  • Hansa Biopharma AB/Sarepta Therapeutics
  • LogicBio Therapeutics
  • Passage Bio
  • Sarepta Therapeutics
  • Sarepta Therapeutics/Roche
  • Selecta Biosciences
  • Spark Therapeutics/Roche
  • StrideBio
  • Taysha Gene Therapies
  • UniQure
  • 4D Molecular Therapeutics
  • Others
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going